Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Conditions: Multiple Myeloma; Relapsed Refractory Multiple Myeloma Interventions: Drug: Elotuzumab, pomalidomide, dexamethasone; Drug: Anti-LAG-3 Monoclonal Antibody BMS-986016, pomalidomide, dexamethasone; Drug: Anti-TIGIT Monoclonal Antibody BMS-986207, pomalidomide, dexamethasone Sponsors: Multiple Myeloma Research Consortium; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials